Immatics Announces Pricing of $150 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...
Immatics Announces Proposed $150 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...
Immatics: A Promising TCR Pipeline
Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...
FierceBiotech6d
Immatics' cell therapy leapfrogs into phase 3 on strength of early-stage survival data
Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...
Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics
Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX – Research Report) on October 11 and set a price target ...
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering ...
The Pharma Letter6d
Immunotherapy firm Immatics prices $150 million public offering
German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...
Business Insider6d
Immatics Announces Pricing of $150 Million Public Offering
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T ...
Immatics Shares Drop After Launching $150M Public Offering
Immatics shares were down 10% to $9.95 after the company began a proposed $150 million underwritten public offering of its ordinary shares.
Nasdaq6d
Immatics Reports Updated Phase 1b Data Of IMA203 In Melanoma Patients
(RTTNews) - Immatics N.V. (IMTX) Thursday reported updated data from the Phase 1b study of its ACTengine cell therapy IMA203 in melanoma patients. ACTengine is a personalized therapy in which a ...